Wegovy and Heart Health: What the SELECT Trial Actually Showed

“Heart benefits” can describe several different outcomes: a lower blood-pressure reading, better symptoms or fewer heart attacks and strokes. The SELECT trial tested the last category. Understanding that distinction helps you ask a more useful question than whether a weight-loss medicine is generally good for the heart.

This guide explains the trial and its limits. It does not establish which cardiovascular treatment you personally need.

Who was enrolled in SELECT?

SELECT enrolled 17,604 adults aged 45 or older with a BMI of at least 27, established cardiovascular disease and no diabetes. Participants received weekly subcutaneous semaglutide, targeting 2.4 mg, or placebo alongside standard care¹. This was a high-risk population with existing disease, rather than a trial of preventing a first cardiovascular problem in otherwise healthy people.

Before applying its result to yourself, ask whether your diagnosis resembles the trial population. Risk factors alone and established cardiovascular disease are different clinical situations. A clinician can explain which evidence applies without turning a study's entry criteria into a self-diagnosis.

What did the trial find?

The main outcome combined cardiovascular death, nonfatal heart attack and nonfatal stroke. At a mean follow-up of 39.8 months, a first event occurred in 569 of 8,803 semaglutide participants, or 6.5%, compared with 701 of 8,801 placebo participants, or 8.0%. The hazard ratio was 0.80, with a 95% confidence interval of 0.72 to 0.90¹.

Those reported percentages differ by about 1.5 percentage points. The widely quoted 20% reduction describes the relative hazard, not a 20-percentage-point fall in the number of people having an event. Both measures help interpret the result, and neither predicts one person's outcome.

The study was funded by Novo Nordisk. Random assignment and the prespecified outcome strengthen the evidence, while the study population, treatment duration and product remain important boundaries.

What does the current FDA indication cover?

FDA approved Wegovy injection for reducing cardiovascular death, heart attack and stroke risk in adults with cardiovascular disease and overweight or obesity in March 2024². The June 2026 prescribing information now includes cardiovascular-risk reduction for both Wegovy injection and Wegovy tablets³.

Keep the timeline clear: SELECT studied an injection. A current tablet indication does not mean the participants in SELECT took a tablet. If you are comparing formulations, ask the clinician to explain the evidence, administration requirements and product labeling relevant to the one being prescribed. Our Wegovy pill versus injection guide covers those practical differences.

What the result does not establish

SELECT was not a head-to-head trial against tirzepatide. It cannot determine which medicine is best for every person with heart disease. A weight-loss comparison answers a different question from a cardiovascular-outcomes comparison; the semaglutide versus tirzepatide guide helps separate those decisions.

The evidence also does not automatically transfer to compounded semaglutide. FDA explains that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing⁴. A shared ingredient name is insufficient to claim the same demonstrated cardiovascular benefit for a different preparation.

Nor should a successful trial be read as an instruction to replace existing heart treatment. Ask how the proposed medicine fits your current plan, including who coordinates prescriptions and follow-up. Do not stop established medicines because a new treatment has an additional benefit.

Benefits need to be weighed against tolerability

In SELECT, adverse events led to permanent discontinuation of the trial product in 16.6% of the semaglutide group versus 8.2% of the placebo group¹. A reduction in cardiovascular events does not mean everyone could comfortably continue treatment.

Tell the prescriber about previous reactions and symptoms that could make eating, drinking or taking other medicines difficult. Our semaglutide side-effects guide explains common trial findings, while the laboratory-monitoring guide helps frame follow-up questions. Get individualized instructions about symptoms and medicine changes rather than interpreting a trial average as reassurance about an unassessed problem.

For possible heart-attack or stroke symptoms, seek emergency help. A medication discussion or online message is not an appropriate substitute for urgent evaluation.

Ask the insurer about the actual indication

Ask whether your plan covers the prescribed Wegovy formulation for cardiovascular-risk reduction, which documentation it requires and whether prior authorization applies. An indication on the label does not, by itself, settle your plan's benefits, cost sharing or approval decision.

Bring the diagnosis and relevant records to the prescriber rather than relying on an advertisement that says heart benefits unlock coverage. Our GLP-1 prior-authorization guide explains how to distinguish missing documentation from a benefit exclusion. Ask for a written decision if coverage is denied.

Compare services after deciding on the treatment

If your clinician recommends a brand-name option, compare the care service and medication charge separately. The Ro review and Sesame Care review describe published membership and medication arrangements. These are service reviews, not endorsements of either program's ability to manage your cardiovascular disease.

Use the Wegovy and Ozempic cost board to investigate pricing, then confirm that the quotation is for the prescribed product and dose. Ask whether the online service can share records with your existing clinician, who handles side effects and what happens if treatment is interrupted. Those practical answers make a promising research result usable in a real care plan.